FASgen is pleased to report the publication of important research results for lung cancer treatment using FAS093, one of the Company’s proprietary compounds. In a long-standing cooperation with The Johns Hopkins Oncology Center, FASgen supported research into the selective inhibition of fatty acid synthase (FASi) at the Hopkins Oncology Center as a potential therapeutic agent against various forms of solid tumor cancers. In the recently reported study results, researchers at the Hopkins Oncology Center found that FAS093 significantly inhibited growth of several different xenograft tumors from human NSCLC cell lines. These extremely interesting results appear in the article, “Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment,” Gabrielson et al, Clin Cancer Res 200l, 13(23) 7139-7145 (Dec. 1, 2007).